Evidence of underdiagnosis of myasthenia gravis in older people

Vincent A; Clover L; Buckley C; Grimley Evans J; Rothwell P M; Vincent, A; Clover, L; Buckley, C; Grimley Evans, J; Rothwell, P M; UK Myasthenia Gravis Survey
August 2003
Journal of Neurology, Neurosurgery & Psychiatry;Aug2003, Vol. 74 Issue 8, p1105
Academic Journal
journal article
Background: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoantibodies directed at the acetylcholine receptor (AChR) on the postsynaptic membrane of the neuromuscular junction. There is anecdotal evidence that the diagnosis is sometimes missed in older patients.Objective: To examine the incidence and age distribution of positive AChR antibodies in samples referred to diagnostic laboratories in the UK, and the prevalence of positive AChR antibodies in samples from a cohort of older individuals.Methods: Positive AChR antibody tests were identified from all UK centres registered for the assay with the European quality assurance scheme (EQAS) during 1997-99, and the age and sex specific incidence was calculated, based on the UK population. The prevalence of AChR antibodies in sera from a sample of 2000 individuals aged > or =60 years was determined.Results: 3183 individuals had positive AChR antibody tests on routine screening during the years 1997 to 1999 in the UK, giving an annual incidence of 1.8/100 000. In both sexes, the age specific incidence rose steeply between the ages of 45 and 74, reaching 9.9/100 000 in men, and then fell, with a sharp decline above the age of 80. In the prevalence study, whereas only one serum from individuals aged 60-74 years was positive for AChR antibodies (0.12%), sera from eight individuals aged > or =75 years were positive (0.7%). Only one had a previous clinical diagnosis of myasthenia gravis but four others had histories of stroke or transient ischaemic attacks.Conclusions: The sharp fall in the incidence of clinically recognised myasthenia gravis in people over 80 years of age in our national AChR antibody incidence study, and the high prevalence of previously unrecognised positive AChR antibodies in those > or =75 years old, suggest that myasthenia gravis may be substantially underdiagnosed in older people.


Related Articles

  • Anti-LRP4 Myasthenia Gravis. Rubin, Michael // Neurology Alert;Jul2013, Vol. 31 Issue 11, p81 

    AMONG PATIENTS WITH MYASTHENIA GRAVIS (MG), APPROXIMATELY HAVE 80% serum autoantibodies directed against the nicotinic acetylcholine receptor, 5-10% have autoantibodies directed against the tyrosine kinase muscle-specific kinase (MuSK), and, in the remainder, the autoimmune target is unknown....

  • Predictors of outcome of myasthenic crisis. Liu, Nan; Liu, Qi; Wu, Xiujuan; Liu, Kangding; Vadis, Quo // Neurological Sciences;May2015, Vol. 36 Issue 5, p801 

    No abstract available.

  • Myasthenia Gravis: Analysis of Serum Autoantibody Reactivities to 1827 Potential Human Autoantigens by Protein Macroarrays. Becker, Anne; Ludwig, Nicole; Keller, Andreas; Tackenberg, Björn; Eienbröker, Christian; Oertel, Wolfgang H.; Fassbender, Klaus; Meese, Eckart; Ruprecht, Klemens // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background: Myasthenia gravis is a disorder of neuromuscular transmission associated with autoantibodies against the nicotinic acetylcholine receptor. We have previously developed a customized protein macroarray comprising 1827 potential human autoantigens, which permitted to discriminate sera...

  • PATH49 Use of intravenous immunoglobulin by neurologists in the UK: reporting from year 1 of the DoH IVIG database. M Lunn // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe21 

    Following a critical shortage of IVIG in the UK in 2006, the DoH commissioned a review of use. There was a perception that unlicensed indications for IVIG were proliferating without supportive clinical evidence, and that usage was increasing. The Demand Management Plan, Clinical Guidelines for...

  • Immune homeostasis and target therapy for myasthenia gravis. LIU Wei-bin // Chinese Journal of Contemporary Neurology & Neurosurgery;Oct2014, Vol. 14 Issue 10, p839 

    No abstract available.

  • Autoimmunity: Controlling promiscuity. Bird, Lucy // Nature Reviews Immunology;Oct2007, Vol. 7 Issue 10, p751 

    The article presents a research on autoimmunity focusing on controlling promiscuity. Peripheral tissue antigens in the thymus are means to eliminate developing T cells before they reach the periphery. The authors propose that autoantigen genes may affect the co-transcriptional activity in thymic...

  • Neuromuskuläre Krankheiten waren schon immer schwer zu diagnostizieren. Claus, D. // Der Nervenarzt;Jun2013, Vol. 84 Issue 6, p738 

    The Deutsche Zeitschrift fuer Nervenheilkunde (German Journal for Neurology) was founded as a specifically neurological journal at the end of the nineteenth century and soon became a European platform for scientific discussion of neurological topics. Papers also came from the USA, Scandinavia...

  • Samuel Goldflam (1852-1932). Grzybowski, Andrzej; Sak, Jarosław // Journal of Neurology;Oct2012, Vol. 259 Issue 10, p2264 

    A biography of Samuel Goldflam, a Polish neurologist, is presented. He was born on February 15, 1852 in Warsaw, Poland and studied at the Imperial University. He then worked as an assistant for internal diseases at the Therapeutic Clinic of Imperial University. He is considered as pioneers in...

  • Myasthenia gravis: Association of British Neurologists' management guidelines. Sussman, Jon; Farrugia, Maria E.; Maddison, Paul; Hill, Marguerite; Leite, M. Isabel; Hilton-Jones, David // Practical Neurology (BMJ Publishing Group);Jun2015, Vol. 15 Issue 3, p199 

    Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a...


Read the Article


Sign out of this library

Other Topics